High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.

Vourc'h M, Huard D, Le Penndu M, Deransy R, Surbled M, Malidin M, Mahe PJ, Guitton C, Roquilly A, Malard O, Feuillet F, Rozec B, Asehnoune K.

Open source

DOI
10.1016/j.eclinm.2023.101998
Published
2023-05-22
Container
EClinicalMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2023.101998,
  title = {High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.},
  author = {Vourc'h M and  Huard D and  Le Penndu M and  Deransy R and  Surbled M and  Malidin M and  Mahe PJ and  Guitton C and  Roquilly A and  Malard O and  Feuillet F and  Rozec B and  Asehnoune K.},
  year = {2023},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2023.101998},
  url = {https://doi.org/10.1016/j.eclinm.2023.101998}
}

RIS

TY  - JOUR
TI  - High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.
AU  - Vourc'h M
AU  -  Huard D
AU  -  Le Penndu M
AU  -  Deransy R
AU  -  Surbled M
AU  -  Malidin M
AU  -  Mahe PJ
AU  -  Guitton C
AU  -  Roquilly A
AU  -  Malard O
AU  -  Feuillet F
AU  -  Rozec B
AU  -  Asehnoune K.
PY  - 2023
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2023.101998
UR  - https://doi.org/10.1016/j.eclinm.2023.101998
ER  - 

APA

M, V., D, H., M, L. P., R, D., M, S., M, M., PJ, M., C, G., A, R., O, M., F, F., B, R., & K., A. (2023). High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.101998

Source records